Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HOTH 
Hoth Therapeutics Inc (HOTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HOTH (1-star) is a SELL. SELL since 1 days. Profits (-14.79%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.82% | Avg. Invested days 50 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.04M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 0.67 | 52 Weeks Range 0.65 - 2.79 | Updated Date 08/28/2025 |
52 Weeks Range 0.65 - 2.79 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.31 | Actual -0.17 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.11% | Return on Equity (TTM) -104.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7050640 | Price to Sales(TTM) - |
Enterprise Value 7050640 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 13259000 | Shares Floating 13194721 |
Shares Outstanding 13259000 | Shares Floating 13194721 | ||
Percent Insiders 0.5 | Percent Institutions 1.98 |
Upturn AI SWOT
Hoth Therapeutics Inc
Company Overview
History and Background
Hoth Therapeutics, Inc., founded in 2017, is a biopharmaceutical company focused on developing new therapies for unmet medical needs. It has primarily focused on dermatological conditions and is in early stages of development.
Core Business Areas
- Dermatology: Focuses on developing therapies for dermatological conditions like atopic dermatitis (eczema). Their lead product candidates are in preclinical stages.
- Other Indications: Exploring potential therapies for other indications including cancer. All products are in preclinical stages.
Leadership and Structure
The leadership team consists of experienced executives and scientists in the pharmaceutical industry. The organizational structure is typical for a small, research-focused biopharmaceutical company.
Top Products and Market Share
Key Offerings
- HT-001 (Atopic Dermatitis): A topical formulation for atopic dermatitis. Currently in preclinical development. Market share is currently 0% as product is not on the market. Competitors include Regeneron (REGN) and Sanofi (SNY) with Dupixent, as well as various topical steroid treatments.
- BioLexa Platform: A novel platform with potential for treating various diseases, including cancer and inflammatory conditions. Currently in preclinical development. Market share is currently 0% as product is not on the market. Competitors depend on the indication being targeted.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. Developing new therapies is a lengthy and expensive process with high failure rates.
Positioning
Hoth Therapeutics is a small player in the biopharmaceutical industry, focusing on niche markets. Their success depends on the clinical success of their product candidates.
Total Addressable Market (TAM)
The TAM for atopic dermatitis and cancer therapies is significant, worth billions of dollars. Hoth Therapeutics is positioned to capture a small portion of this TAM if their therapies are successful.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Early stage of development
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expanding into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure to obtain funding
Competitors and Market Share
Key Competitors
- REGN
- SNY
- LLY
Competitive Landscape
Hoth Therapeutics faces intense competition from larger, more established pharmaceutical companies with greater resources. Their competitive advantage lies in their innovative technology platform and focus on unmet medical needs, but their success hinges on clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the early stage of development. Growth depends on securing partnerships and successful clinical trial outcomes.
Future Projections: Future projections are highly uncertain and depend on the success of their product candidates. Analyst estimates are not available in the prompt.
Recent Initiatives: Recent initiatives would involve advancing their product candidates through preclinical and clinical development.
Summary
Hoth Therapeutics is a high-risk, high-reward biopharmaceutical company. It has an innovative platform and is targeting unmet medical needs, which are positive. However, it faces significant challenges, including limited financial resources, competition from larger companies, and the inherent risks of drug development. Its success depends on positive clinical trial outcomes and securing partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in Hoth Therapeutics carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hoth Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-02-15 | Founder, President, CEO & Chairman Mr. Robb Knie | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://hoththerapeutics.com |
Full time employees 2 | Website https://hoththerapeutics.com | ||
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.